Content about Perrigo

May 18, 2012
Perrigo launches store-brand Prevacid 24HR

Perrigo on Friday announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug application for lansoprazole capsules in the 15-mg strength.

April 12, 2012
Perrigo to launch store-brand Mucinex equivalent

Perrigo on Thursday announced that it has initiated shipments of its guaifenesin extended-release tablets in the 600-mg strength, a generic version of Mucinex.

March 2, 2012
Perrigo launches generic version of Rogaine 5% foam

Perrigo announced that it has initiated market launch and made its first shipments of minoxidil 5% foam, which is a generic version of Rogaine 5% foam hair regrowth treatment, to its retail and wholesale customers. Minoxidil 5% foam is marketed under store- or own-label brands.

February 17, 2012
Switching things up

Clarinex (desloratadine), the next-generation prescription allergy remedy to the second-generation Claritin, is 1-of-3 blockbuster prescription medicines that may make the crossover from prescription-only to over-the-counter in the near future.

February 14, 2012
Perrigo launches store-brand equivalent to Claritin-D

Perrigo on Tuesday announced that it has begun shipping Loratadine-D 12-hour extended-release tablets.

February 7, 2012
Perrigo reports Q2

New product sales and the acquisition of Paddock Labs prompted second-quarter net sales to jump 17% to $838 million for Perrigo for fiscal year 2012, the drug maker said.

January 23, 2012
Perrigo files for approval of generic nasal allergy drug

Perrigo is seeking approval from the Food and Drug Administration for a drug used to treat allergies in adolescents and adults, the company said Monday.

January 13, 2012
Perrigo appoints Johnson head of OTC product development

Perrigo on Thursday named Bruce Johnson to VP consumer healthcare research and development. Johnson will lead new product development for the supplier in the U.S. market.

January 10, 2012
Perrigo forecasts sunny days now and in the future for private-label OTC

Over the past year, store-brand sales of over-the-counter products have helped maintain a slight growth through the sector, and with the number of proposed prescription-to-OTC switches on the horizon, the future looks especially bright, Joe Papa, Perrigo chairman, president and CEO, told attendees of the 30th Annual J.P. Morgan Healthcare Conference held Monday.

January 9, 2012
Perrigo buys CanAm Care

Drug maker Perrigo is buying a privately owned distributor of diabetes products, the company said Monday.

January 4, 2012
Perrigo announces summertime availability of desloratadine in Rx and OTC

Perrigo last week announced that it has received final Food and Drug Administration approval for its generic prescription allergy remedy desloratadine 5 mg, the generic equivalent to Schering-Plough's Clarinex.

November 28, 2011
Perrigo gains approval for store brand Mucinex

Perrigo on Monday announced that it received final approval from the Food and Drug Administration for its store-brand version of Mucinex tablets.

November 21, 2011
Perrigo names M&A vet to corporate development post

Perrigo on Monday named Christopher Roop to the post of VP corporate development.

November 15, 2011
Perrigo gains approval for new store-brand infant formula offering

Perrigo on Tuesday announced it received Food and Drug Administration clearance to market and distribute infant formula that contains 100% partially hydrolyzed whey protein.

November 3, 2011
FDA approves generic version of Merck's Elestat ophthalmic solution

The Food and Drug Administration has approved a drug made by Perrigo and PharmaForce/Luitpold Pharmaceuticals for treating eye allergies, Perrigo said.

November 2, 2011
Perrigo seeks approval for generic version of Abbott's Androgel

Drug maker Perrigo has filed for regulatory approval of a generic topical drug for treating testosterone deficiency, prompting a patent infringement suit from the branded version's manufacturer.

October 6, 2011
Perrigo receives tentative FDA approval for generic scalp dermatosis drug

The Food and Drug Administration has granted tentative approval to a drug made by Perrigo for dermatosis of the scalp.

September 12, 2011
Perrigo works to educate on kids’ dosing changes

Perrigo this summer developed a healthcare professional outreach strategy, educating pediatricians, for example, around the company’s new infants’ and children’s acetaminophen dosing and packaging changes.

August 30, 2011
FDA approves Perrigo, Cobrek dermatitis drug

The Food and Drug Administration has approved a treatment for dermatitis made by Perrigo under a collaboration with Chicago-based Cobrek Pharmaceutical.

August 24, 2011
M&A: Multitudinous and ample

The final outcome of the battle between Israel’s Teva Pharmaceutical Industries and Canada’s Valeant Pharmaceuticals International to buy Cephalon serves as a good illustration of why it helps to have a plan B.


August 17, 2011
Perrigo 2012 targets: Prevacid 24HR and Align; Lipitor on the horizon?

Perrigo is planning to launch more than 45 new products in fiscal 2012 that will translate into approximately $190 million added to annual Perrigo sales, Perrigo chairman, president and CEO Joe Papa told analysts during the company's fourth-quarter conference call Tuesday.

August 16, 2011
Perrigo sales, profits increase in fiscal 2011

Generic drug maker Perrigo reported sales of $2.76 billion and profits of $341 million in fiscal year 2011, according to an earnings report released Tuesday.

July 27, 2011
Perrigo closes acquisition of Paddock Labs

Generic drug maker Perrigo has closed its purchase of Paddock Labs, the company said Tuesday.

July 22, 2011
Perrigo to market store-brand smoking-cessation gum

Perrigo on Thursday announced that it has received approval from the Food and Drug Administration to market a cinnamon-flavored, over-the-counter coated nicotine polacrilex gum USP in 2-mg and 4-mg strengths.

June 30, 2011
Perrigo's acquisition of Paddock Labs put on hold

Perrigo on Wednesday announced that its closing date to complete the acquisition of Paddock Labs — a generic pharmaceutical and specialty over-the-counter products manufacturer — has been delayed by an extended Federal Trade Commission review.

© 2012 Drug Store News. All Rights Reserved.